PubMed HealthSearch

Biomedical subjects

A Wiseman

Publications and source records attributed to A Wiseman.

At least 19 recordsLinked to original sources

The organisation of production of genetically-engineered proteins in yeast.

The use of a variety of genetic-engineering techniques to introduce foreign DNA into living yeast cells has resulted in the production in these cells of the corresponding proteins. These include enzymes, antibodies, vaccines, anti-viral agents, and hormones. This article discusses the techniques of genetic engineering in yeast and suggests the lines of future progress in the economic production of novel proteins for use in therapy.

Plasmids

Bovine leucosis (lymphosarcoma): a clinical study of 60 pathologically confirmed cases.

The clinical features of 60 pathologically confirmed cases of bovine leucosis (lymphosarcoma) are described. The majority of cases could be classified into one of four distinct clinical forms, ie, juvenile multicentric, thymic, skin and adult multicentric. Diagnosis of leucosis in animals with these forms was possible on clinical grounds alone. Five animals, four of which were adult, could not be thus classified and diagnosis required haematological and, or, pathological examinations. The clinical, epidemiological and serological findings would suggest that the cases were examples of sporadic bovine leucosis.

Animals

Cytoplasmically inherited mutations of a human cell line resulting in deficient mitochondrial protein synthesis.

A large number of mutants deficient in mitochondrial protein synthesis (mtPS-) have been isolated from the human cell line VA2-B by subjecting cells partially depleted of their mtDNA to mutagenic treatments thought to be specific for mtDNA. Each of these mtPS- mutants has less than 10% of the wild-type rate of mitochondrial protein synthesis, exhibits reduced cytochrome oxidase and rutamycin sensitive ATPase activities, requires high concentrations of glucose, and grows indefinitely in the presence of 100 micrograms/ml of chloramphenicol (CAP). Fusion of cytoplasts from seven mtPS- mutants to the nucleated thioguanine-resistant VA2-B derivative TG-6 has yielded numerous cybrid clones which grow in CAP plus thioguanine, whereas almost no clones have resulted from the fusion of nucleated mtPS- cells to TG-6 cells: these results suggest that the gene(s) coding for the phenotype of mtPS- cells is localized in the cytoplasm (mtDNA?).

Cell Line

Immunoglobulin containing cells in the bronchopulmonary system of non-pneumonic and pneumonic calves.

In an examination of the immunoglobulin containing cells in the respiratory mucosa of three-month-old non-pneumonic calves, IgA was found to be the predominant plasma cell type. In calves with cuffing pneumonia there was a marked increase in the plasma cell population in the bronchial wall and IgG1 cells became the major cell type. Similarly in calves with an exudative type of pneumonia IgG1 plasma cells were the significant cell type in the respiratory mucosa but the total number of plasma cells was similar to that found in the non-pneumonic animals. The immunohistochemical results suggest that IgA and, to a lesser extent, IgM are both transported across the mucous membrane via bronchial epithelial secretory cells and submucosal glands.

Animals

Regulation of the biosynthesis of cytochrome P-450 in brewer's yeast. Role of cyclic AMP.

The drug metabolising enzyme cytochrome P-450 has been studied in great detail in mammalian systems and its presence in microorganisms is also well established. However, neither its function nor its means of control in brewer's yeast, Saccharomyces cerevisiae, has been investigated. We demonstrate here using yeast protoplasts that it is the intracellular concentration of cyclic AMP which controls, by repression, the de novo synthesis of the enzyme, and also that cyclic AMP concentrations are in turn inversely related to the concentration of glucose in the yeast growth medium.

Cyclic AMP

Reversible tenfod reduction in mitochondria DNA content of human cells treated with ethidium bromide.

Cells of the human line VA2-B in suspension culture have been treated with very low concentrations of ethidium bromide for the purpose of reducing the amount of mitochondrial DNA (mit-DNA) per cell. Cells maintained in the presence of 5 ng/ml ethidium bromide grew at a normal rate for three days; thereafter, their doubling time gradually increased to a stable value of about 60 h. In these cells, the rate of 3H thymidine incorporation into mit-DNA decreased very rapidly to approximately 60% of the normal, and remained thereafter at this level, while the amount of mit-DNA per cell stabilized around a level of 70--80% of the control. In cells long-term treated with 5 ng/ml ethidium bromide, the rate of mitochondrial protein synthesis was about 35% of the normal, and the cytochrome c oxidase activity about 50% of the control. Cells treated with 20 ng/ml of the drug underwent 3--4 cell doublings at control rates, then gradually stopped growing, and eventually died. In these cells, the rate of incorporation of 3H thymidine into mit-DNA was reduced to 50% of the control value after 10 min treatment with ethidium bromide, and became barely detectable after three cell doublings. At this time, the cells had on the average less than 10% of the control amount of mit-DNA, the rate of mitochondrial protein synthesis was reduced to 3% of the normal, and the specific activities of cytochrome c oxidase and rutamycin-sensitive ATPase were less than 20% of the control values. In spite of these marked changes, the cells exhibited only a 20--30% loss in cell viability, as estimated by cloning efficiency, after three days of exposure to the drug. Cells treated with ethidium bromide at 20 ng/ml for three days, and then transferred to drug-free medium, recovered a near-to-normal growth rate and cloning efficiency and a near-to-normal rate of synthesis and amount of mit-DNA in about five days.

Cell Line

Transmission studies with bovine malignant catarrhal fever.

The intravenous administration of whole blood from a pathologically confirmed field case of bovine malignant catarrhal fever (MCF) resulted in the appearance of the disease in three of five experimental calves 18 to 28 days later. Infection was maintained by serial calf transmissions, and produced clinical and pathological changes identical to those of the field disease for a total of 10 passages. The sixth passage involved the simultaneous infection of 10 calves from a single donor animal; six of the 10 recipients developed the typical disease after incubation periods ranging from 20 to 36 days and in each of these MCF was confirmed by pathological examination. In addition, clinical and pathological changes in the four other calves which were slaughtered either seven or 14 days post-infection suggested that they too would have developed typical clinical signs had they been allowed to survive for the necessary length of time. The results of a detailed study of the onset, progress and duration of the clinical signs of experimentally induced MCF are presented and the opportunity has been taken to discuss the available information regarding the transmission of MCF under experimental conditions and in the field.

Animals